EyePoint Pharmaceuticals (EYPT) Scheduled to Post Earnings on Wednesday

EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Rating) is scheduled to be releasing its earnings data before the market opens on Wednesday, May 4th. Analysts expect EyePoint Pharmaceuticals to post earnings of ($0.50) per share for the quarter.

EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Rating) last posted its quarterly earnings results on Thursday, March 3rd. The company reported ($0.59) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.09). EyePoint Pharmaceuticals had a negative return on equity of 46.76% and a negative net margin of 159.70%. The business had revenue of $11.19 million during the quarter, compared to analysts’ expectations of $9.75 million. During the same quarter in the prior year, the firm earned ($1.01) EPS. On average, analysts expect EyePoint Pharmaceuticals to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Shares of EYPT stock traded down $0.24 during mid-day trading on Thursday, hitting $11.55. The company’s stock had a trading volume of 197 shares, compared to its average volume of 216,123. EyePoint Pharmaceuticals has a 52-week low of $7.30 and a 52-week high of $21.50. The business has a 50-day moving average price of $11.87 and a 200 day moving average price of $12.30. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.90 and a current ratio of 10.05. The stock has a market cap of $393.21 million, a price-to-earnings ratio of -5.75 and a beta of 1.18.

Several analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $24.00 price objective on shares of EyePoint Pharmaceuticals in a report on Friday, March 4th. Zacks Investment Research raised EyePoint Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, January 17th. StockNews.com assumed coverage on EyePoint Pharmaceuticals in a report on Thursday, March 31st. They set a “hold” rating for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of EyePoint Pharmaceuticals in a report on Friday, March 4th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, EyePoint Pharmaceuticals currently has an average rating of “Buy” and an average target price of $29.50.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EYPT. Goldman Sachs Group Inc. boosted its stake in shares of EyePoint Pharmaceuticals by 1,491.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 622,018 shares of the company’s stock worth $7,614,000 after acquiring an additional 582,925 shares during the period. BlackRock Inc. lifted its position in shares of EyePoint Pharmaceuticals by 21.0% in the fourth quarter. BlackRock Inc. now owns 1,440,631 shares of the company’s stock worth $17,633,000 after buying an additional 249,998 shares in the last quarter. D. E. Shaw & Co. Inc. lifted its position in shares of EyePoint Pharmaceuticals by 309.5% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 278,672 shares of the company’s stock worth $3,411,000 after buying an additional 210,623 shares in the last quarter. Millennium Management LLC lifted its position in shares of EyePoint Pharmaceuticals by 231.2% in the fourth quarter. Millennium Management LLC now owns 123,203 shares of the company’s stock worth $1,508,000 after buying an additional 86,000 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in shares of EyePoint Pharmaceuticals by 541.4% in the fourth quarter. Bank of America Corp DE now owns 75,800 shares of the company’s stock worth $928,000 after buying an additional 63,982 shares in the last quarter. 70.85% of the stock is owned by hedge funds and other institutional investors.

About EyePoint Pharmaceuticals (Get Rating)

EyePoint Pharmaceuticals, Inc, a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery.

Featured Articles